In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

DelMar Pharmaceuticals Inc. Trade Record

NASDAQ:DMPI DelMar Pharmaceuticals Inc stock gains 34.53% Exit Sep 27, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart DMPI Sep 7, 2018, priceSeries
About DelMar Pharmaceuticals Inc

DelMar Pharmaceuticals, Inc., a clinical stage company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; and collaboration with the University of Texas MD Anderson Cancer Center. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.

Trade Information
Trade Type
LONG
ReliabilityScore™
82.22
Entry Date
Sep 7, 2018
Entry Price
5.60
Sell Date
Sep 27, 2018
Sell Price
7.53
Net Gain
34.53%
Hold Time
14 Trading Days